{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:48:00Z","timestamp":1792738080732,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,11,1]],"date-time":"2004-11-01T00:00:00Z","timestamp":1099267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,11,1]],"date-time":"2004-11-01T00:00:00Z","timestamp":1099267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2004,11,1]],"date-time":"2004-11-01T00:00:00Z","timestamp":1099267200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2004,11,1]],"date-time":"2004-11-01T00:00:00Z","timestamp":1099267200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2004,11,1]],"date-time":"2004-11-01T00:00:00Z","timestamp":1099267200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2004,11,1]],"date-time":"2004-11-01T00:00:00Z","timestamp":1099267200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2004,11,1]],"date-time":"2004-11-01T00:00:00Z","timestamp":1099267200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2004,11]]},"DOI":"10.1016\/j.atherosclerosis.2004.06.011","type":"journal-article","created":{"date-parts":[[2004,8,31]],"date-time":"2004-08-31T09:27:23Z","timestamp":1093944443000},"page":"137-145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Increased apoC-III production is a characteristic feature of patients with hypertriglyceridemia"],"prefix":"10.1016","volume":"177","author":[{"given":"Jeffrey S.","family":"Cohn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Batal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Jacques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orval","family":"Mamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Davignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib1","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/0002-8703(86)90296-6","article-title":"The triglyceride issue: a view from Framingham","volume":"112","author":"Castelli","year":"1986","journal-title":"Am. Heart J."},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1161\/01.ATV.11.1.2","article-title":"Plasma triglyceride and coronary artery disease","volume":"11","author":"Austin","year":"1991","journal-title":"Arterioscler. Thromb."},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib3","doi-asserted-by":"crossref","unstructured":"NIH Consensus Development Panel on Triglyceride, High-Density Lipoprotein and Coronary Heart Disease. Triglyceride, high-density lipoprotein, and coronary heart disease. JAMA 1993;269:505\u201310.","DOI":"10.1001\/jama.1993.03500040071040"},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib4","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/archinte.1992.00400130054004","article-title":"Two different views of the relationship of hypertriglyceridemia to coronary heart disease. Implications for treatment","volume":"152","author":"Grundy","year":"1992","journal-title":"Arch. Int. Med."},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1067\/mhj.2002.130301","article-title":"High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease","volume":"144","author":"Gotto","year":"2002","journal-title":"Am. Heart J."},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib6","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/00041433-200212000-00003","article-title":"HDL and triglyceride as therapeutic targets","volume":"13","author":"Fruchart","year":"2002","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib7","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1161\/01.ATV.19.3.472","article-title":"Role of apoCs in lipoprotein metabolism: functional differences between apoC1, apoC2, and apoC3","volume":"19","author":"Jong","year":"1999","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib8","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00041433-200106000-00009","article-title":"Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism","volume":"12","author":"Shachter","year":"2001","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib9","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.1016\/S0021-9258(19)42416-2","article-title":"The complete amino acid sequence of alanine apolipoprotein (apoC-3), and apolipoprotein from human plasma very low density lipoproteins","volume":"249","author":"Brewer","year":"1974","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib10","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0022-2275(20)38497-2","article-title":"Apolipoprotein gene expression in the rabbit: abundance, size, and distribution of apolipoprotein mRNA species in different tissues","volume":"29","author":"Lenich","year":"1988","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib11","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/0026-0495(79)90004-0","article-title":"Apolipoprotein C-II and C-III levels in hyperlipoproteinemia","volume":"28","author":"Schonfeld","year":"1979","journal-title":"Metabolism"},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib12","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/0005-2760(80)90016-8","article-title":"Quantitative determination of human apolipoprotein C-III by electroimmunoassay","volume":"617","author":"Curry","year":"1980","journal-title":"Biochem. Biophys. Acta"},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib13","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/S0022-2275(20)37352-1","article-title":"Quantitation of human apolipoprotein C-III and its subspecies by radioimmunoassay and analytical isoelectric focusing: abnormal plasma triglyceride-rich lipoprotein apolipoprotein C-III subspecie concentrations in hypertriglyceridemia","volume":"22","author":"Kashyap","year":"1981","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib14","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/S0022-2275(20)37424-1","article-title":"Plasma lipoprotein distribution of apoC-III in normolipidemic and hypertriglyceridemic subjects: comparison of the apoC-III to apoE ratio in different lipoprotein fractions","volume":"38","author":"Fredenrich","year":"1997","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib15","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1073\/pnas.90.10.4562","article-title":"An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3\u2032 untranslated region polymorphisms","volume":"90","author":"Dammerman","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib16","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1161\/01.ATV.16.8.941","article-title":"Polymorphic markers in apolipoprotein C-III gene flanking regions and hypertriglyceridemia","volume":"16","author":"Surguchov","year":"1996","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib17","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S0022-2275(20)37189-3","article-title":"A variation in the apolipoprotein C-III gene is associated with an increased number of circulating VLDL and IDL particles in familial combined hyperlipidemia","volume":"38","author":"Ribalta","year":"1997","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib18","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1172\/JCI111576","article-title":"Familial apolipoprotein AI and apolipoprotein C-III deficiency. Subclass distribution, composition, and morphology of lipoproteins in a disorder associated with premature atherosclerosis","volume":"74","author":"Forte","year":"1984","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib19","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1172\/JCI115190","article-title":"Apolipoprotein C-III (Lys58mGlu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia","volume":"87","author":"Von Eckardstein","year":"1991","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib20","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1126\/science.2167514","article-title":"Hypertriglyceridemia as a result of human apoCIII gene expression in transgenic mice","volume":"249","author":"Ito","year":"1990","journal-title":"Science (Washington, DC)"},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib21","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1172\/JCI116066","article-title":"Mechanism of hypertriglyceridemia in human apolipoprotein (apo) C-III transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo C-III and reduced apo E on the particles","volume":"90","author":"Aalto-Setala","year":"1992","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib22","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/S0021-9258(17)42171-5","article-title":"Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E","volume":"269","author":"de Silva","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib23","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0021-9258(17)31559-4","article-title":"Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia","volume":"269","author":"Maeda","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib24","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0006-291X(72)80149-9","article-title":"Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein","volume":"46","author":"Brown","year":"1972","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib25","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1161\/01.RES.33.4.403","article-title":"Further observations on the activation and inhibition of lipoprotein lipase by apolipoproteins","volume":"33","author":"Krauss","year":"1973","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib26","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1021\/bi00733a026","article-title":"Cofactor activity of protein components of human very low density lipoproteins in the hydrolysis of triglycerides by lipoprotein lipase from different sources","volume":"12","author":"Havel","year":"1973","journal-title":"Biochemistry"},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib27","first-page":"G805","article-title":"Influence of apolipoprotein E on soluble and heparin-immobilized hepatic lipase","volume":"252","author":"Landis","year":"1987","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib28","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0022-2275(20)37573-8","article-title":"Lipoprotein lipase-enhanced binding of human triglyceride-rich lipoproteins to heparan sulfate: modulation by apolipoprotein E and apolipoprotein C","volume":"37","author":"Van Barlingen","year":"1996","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib29","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0022-2275(20)34342-X","article-title":"Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver","volume":"26","author":"Windler","year":"1985","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib30","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1161\/01.ATV.15.7.963","article-title":"Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII CIII and E","volume":"15","author":"Clavey","year":"1995","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib31","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1074\/jbc.272.50.31348","article-title":"Inhibitory effects of specific apolipoprotein C-III isoforms on the binding of triglyceride-rich lipoproteins to the lipolysis-stimulated receptor","volume":"272","author":"Mann","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib32","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1172\/JCI119456","article-title":"Chylomicronemia due to apolipoprotein C III overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E","volume":"99","author":"Ebara","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib33","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/S0022-2275(20)37316-8","article-title":"Metabolism of C-apolipoproteins: kinetics of C-II, C-III1 and C-III2, and VLDL-apolipoprotein B in normal and hyperlipoproteinemic subjects","volume":"22","author":"Huff","year":"1981","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib34","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/0026-0495(82)90240-2","article-title":"Metabolism of apolipoproteins CII, CI II1, CIII2 and VLDL-B in human subjects consuming high carbohydrate diets","volume":"31","author":"Huff","year":"1982","journal-title":"Metabolism"},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib35","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0021-9150(89)90075-0","article-title":"Apolipoproteins C-II and C-II I metabolism in hypertriglyceridemic patients. Effect of a drastic triglyceride reduction by combined diet restriction and fenofibrate administration","volume":"77","author":"Malmendier","year":"1989","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib36","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/S0022-2275(20)32379-8","article-title":"Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects","volume":"41","author":"Batal","year":"2000","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib37","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1210\/jc.2003-032056","article-title":"Rate of production of plasma and VLDL apoC-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity","volume":"89","author":"Cohn","year":"2004","journal-title":"J. Clin. Endo. Metab."},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib38","series-title":"The metabolic basis of inherited disease","first-page":"1195","article-title":"Type III hyperlipoproteinemia (dysbeta-lipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism","author":"Mahley","year":"1989"},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib39","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1194\/jlr.M200016-JLR200","article-title":"Effect of atorvastatin on plasma apoE metabolism in patients with combined hyperlipidemia","volume":"43","author":"Cohn","year":"2002","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib40","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1172\/JCI114507","article-title":"Measurement of very low density and low density lipoprotein apolipoprotein (apo) B-100 and high density lipoprotein apo A-I production in human subjects using deuterated leucine. Effect of fasting and feeding","volume":"85","author":"Cohn","year":"1990","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib41","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1161\/01.ATV.18.4.655","article-title":"Familial HDL deficiency characterized by hypercatabolism of mature apoA-I but not proapoA-I","volume":"18","author":"Batal","year":"1998","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib42","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1161\/01.ATV.16.1.149","article-title":"Plasma concentration of apolipoprotein E in intermediate-sized remnant-like lipoproteins in normolipidemic and hyperlipidemic subjects","volume":"16","author":"Cohn","year":"1996","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"II-148","key":"10.1016\/j.atherosclerosis.2004.06.011_bib43","article-title":"Level of apoC-III mRNA correlates positively to the secretion of triglyceride-rich VLDL from transfected McA-RH7777 cells","volume":"102","author":"Rahimkhani","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib44","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1161\/01.CIR.81.2.470","article-title":"Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors","volume":"81","author":"Blankenhorn","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib45","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1161\/01.CIR.90.1.42","article-title":"Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild\/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin","volume":"90","author":"Hodis","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib46","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0021-9150(95)05791-9","article-title":"Triglyceride enriched lipoprotein particles correlate with the severity of coronary artery disease","volume":"122","author":"Koren","year":"1996","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib47","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1161\/01.CIR.102.16.1886","article-title":"VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial","volume":"102","author":"Sacks","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib48","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1161\/01.ATV.0000066131.01313.EB","article-title":"LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients","volume":"23","author":"Lee","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib49","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1172\/JCI117717","article-title":"Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates","volume":"95","author":"Staels","year":"1995","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2004.06.011_bib50","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/S0022-2275(20)41090-9","article-title":"Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action","volume":"36","author":"Haubenwallner","year":"1995","journal-title":"J. Lipid Res."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915004003648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915004003648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:28:10Z","timestamp":1758155290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915004003648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,11]]}},"alternative-id":["S0021915004003648"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2004.06.011","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2004,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increased apoC-III production is a characteristic feature of patients with hypertriglyceridemia","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2004.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}